IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive...
IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps...
IGC Pharma (NYSE American: IGC) will be presenting at this month’s Planet MicroCap Showcase: VEGAS 2023; the event is slated for Wednesday, April 26, 2023, at 7:30 p.m. ET. According to the announcement,...
Potomac, Maryland--(Newsfile Corp. - March 22, 2023) - IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced that Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principle...
Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued...
In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational...
India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from...
India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled...
India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published...
India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022....